Fischer Grant M, Mahadevan Navin R, Hornick Jason L, Fletcher Christopher D M, Russell-Goldman Eleanor
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Mod Pathol. 2024 Dec;37(12):100626. doi: 10.1016/j.modpat.2024.100626. Epub 2024 Sep 25.
Undifferentiated melanoma, defined as melanoma that has lost all usual phenotypic and immunohistochemical characteristics of conventional melanoma, can pose significant diagnostic challenges. Molecular studies have advanced our understanding of undifferentiated melanoma by demonstrating that a subset of these tumors harbors known melanoma driver alterations in genes such as BRAF, NRAS, and NF1. However, there is a paucity of data describing genetic alterations that may distinguish undifferentiated melanoma from conventional melanoma. In this study, we directly compared the genomic profiles of undifferentiated melanoma to a cohort of conventional melanomas, including 14 undifferentiated melanoma cases (comprised of 2 primary cases, 2 cutaneous recurrences, and 10 metastases) and a cohort of 127 conventional melanomas including primary, recurrent, and metastatic cases. Targeted sequencing of 447 cancer-associated genes was performed, including identification of mutations and copy number alterations. NRAS was the most frequent melanoma driver in undifferentiated melanoma (8/14 cases, 57%), although notably, only 1 undifferentiated melanoma harbored an NRAS Q61R mutation. Compared with the conventional melanoma cohort, undifferentiated melanoma demonstrated statistically significant enrichment of pathogenic activating RAC1 mutations (6/14 total cases, 43%), including P29S (4/6 cases), P29L (1/6 cases), and D11E (1/6 cases). In addition to providing insight into the molecular pathogenesis of undifferentiated melanoma, these findings also suggest that RAS Q61R immunohistochemistry may have limited utility for its diagnosis. The presence of recurrent RAC1 mutations in undifferentiated melanoma is also notable as these alterations may contribute to mitogen-activated protein kinase pathway-targeted therapy resistance. Furthermore, the RAC1 alterations identified in this cohort have been shown to drive a melanocytic to mesenchymal switch in melanocytes, offering a possible explanation for the undifferentiated phenotype of these melanomas.
未分化黑色素瘤被定义为已丧失传统黑色素瘤所有常见表型和免疫组化特征的黑色素瘤,它可能带来重大的诊断挑战。分子研究通过证明这些肿瘤的一个亚群在BRAF、NRAS和NF1等基因中存在已知的黑色素瘤驱动改变,推进了我们对未分化黑色素瘤的理解。然而,描述可能区分未分化黑色素瘤与传统黑色素瘤的基因改变的数据却很匮乏。在本研究中,我们将未分化黑色素瘤的基因组图谱与一组传统黑色素瘤进行了直接比较,其中包括14例未分化黑色素瘤病例(由2例原发性病例、2例皮肤复发病例和10例转移病例组成)以及一组127例传统黑色素瘤病例,包括原发性、复发性和转移性病例。对447个癌症相关基因进行了靶向测序,包括突变和拷贝数改变的鉴定。NRAS是未分化黑色素瘤中最常见的黑色素瘤驱动基因(8/14例,57%),不过值得注意的是,只有1例未分化黑色素瘤携带NRAS Q61R突变。与传统黑色素瘤队列相比,未分化黑色素瘤显示出致病性激活RAC1突变在统计学上有显著富集(共6/14例,43%),包括P29S(4/6例)、P29L(1/6例)和D11E(1/6例)。除了深入了解未分化黑色素瘤的分子发病机制外,这些发现还表明RAS Q61R免疫组化在其诊断中的效用可能有限。未分化黑色素瘤中反复出现的RAC1突变也值得关注,因为这些改变可能导致丝裂原活化蛋白激酶途径靶向治疗耐药。此外,在该队列中鉴定出的RAC1改变已被证明可驱动黑素细胞向间充质转变,这为这些黑色素瘤的未分化表型提供了一种可能的解释。